Albert Agustinus's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2025
Question
Albert Agustinus, on behalf of Jonathan Chang at Leerink Partners, sought confirmation on whether the company is still on track to present data for the TEBI-AM study in the second half of 2026.
Answer
David Berman, EVP of R&D, confirmed they are on track to complete randomization for TEBI-AM, but the data readout is event-driven. He reiterated the speculation for a readout in the second half of 2026 but noted the timeline will become more precise as more events are accrued over the next six to nine months.